EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Osteoporosis, Hypomagnesemia

In brief

Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). The current trial represents the investigators ongoing effort to discern whether these complications could be averted by effervescent calcium magnesium citrate (EffCaMgCit).

Key facts

Study ID
NCT05998863
Run by
University of Texas Southwestern Medical Center
People needed
0
Starts
2024-04-19
Expected to finish
2026-06-25
Last updated by the study team
2026-06-30

Who can join

Age: 21 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.